VectorXcellerator Programme: Fully funded feasibility studies to support early-stage cell and gene therapy programmes

Webinar: Optimising viral vector manufacturing with CDMO expertise and innovation

News: OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category

Introducing the CAZL Element: A Minimal 3′ UTR Sequence that Imparts Enhanced Expression to Transgenes in Target Cells

September 17, 2024